Fatty acid synthesis is particularly important in the pathogenesis of Trypanosoma brucei, the parasite that is transmitted by the tsetse fly and causes sleeping sickness in humans. T. brucei-in addition to the usual requirement of fatty acids for making cellular membranesneeds large amounts of myristate, a fourteen carbon (C14) fatty acid, to evade the immune system of the mammalian host. In the mammalian bloodstream, T. brucei survives the host immune system by switching surface coats composed of about 10 7 copies of variant surface glycoprotein (VSG) molecules of which T. brucei encodes about 1000 species. Each VSG is attached to the plasma membrane of the parasite by a glycosylphosphatidylinositol (GPI) anchor. Strikingly, the fatty acid chains of the GPI anchor consist exclusively of myristate (Ferguson et al., 1985) . This unique composition renders the organism extremely sensitive to myristate analogs (Doering et al., 1994) . Interestingly, the form of T. brucei that lives in the midgut of the tsetse fly lacks VSGs. Therefore, once an infected fly bites a mammal transferring the trypanosome in the process, the parasite must quickly make or obtain myristate to anchor its protective VSG surface coat. The source of myristate was a longstanding mystery as blood contains little myristate, and it was thought that bloodstream trypanosomes were unable to synthesize fatty acids (Paul et al., 2001 ). Although T. brucei efficiently scavenges myristate from host blood and channels it into VSG anchors, the supply is insufficient to account for the density of parasites observed in blood (Paul et al., 2001) . The solution to this conundrum was the serendipitous finding that T. brucei specifically elongates laurate, a twelve carbon fatty acid, to myristate in vivo Enzymatic steps common to all three pathways are in blue whereas those proteins that act only in the conventional fatty acid synthesis pathways are in black. The mammalian type I system exists as a megasynthase complex in which the activating thiol and the elongation donor exist as domains of the megasynthase. In the type II system and in T. brucei, the enzymatic activities are part of individual proteins. The sequences of the proteins catalyzing a given enzymatic step are not necessarily conserved. A variety of proteins that possess 3-ketoacyl synthase, enoyl reductase, or 3-hydroxyacyl dehydratase activities are found in nature.
tems) (Cronan, 2006) . In plants, fatty acid synthesis until the C18 stage is performed in the chloroplasts using a series of small discrete soluble proteins, each responsible for one reaction of the cycle (called a type II system). This system is derived from the ancestral cyanobacterium endosymbiont and strongly resembles that seen in bacteria (Campbell and Cronan, 2001) . Another type of compartmentalization is seen in the apicomplexan protozoa (exemplified by the parasites that cause malaria and toxoplasmosis) where the responsible type II system lies within an organelle thought to be a remnant from the engulfment of an algal cell (Sonda and Hehl, 2006) . Finally, eukaryotes have a mitochondrial type II system. However, the mitochondrial pathway is of very low synthetic capacity and is thought to be involved in making lipoic acid for the TCA cycle (Cronan et al., 2005) . A key characteristic of both types of fatty acid synthetic systems is that they require a protein that is covalently modified by attachment of a 4′-phosphopantetheine (the nonnucleotide portion of CoA). In type II systems the modified protein is called acyl carrier protein (ACP) because all of the intermediates of fatty acid synthesis are linked to the thiol of the prosthetic group (Campbell and Cronan, 2001 ). The ACPs of type I systems are discrete domains of the polyfunctional proteins (Cronan, 2006) . In Figure 1 the properties of the fatty acid synthetic systems are compared and contrasted with that discovered by Lee and coworkers (Lee et al., 2006) . Given that the butyryl-CoA elongation system in T. brucei appeared to be membrane bound rather than cytosolic and that an inhibitor of type II fatty acid synthesis inhibited T. brucei in vitro fatty acid synthesis, it seemed possible that the synthesis observed by Morita et al. Morita et al., 2000) was due to contamination of the T. brucei membrane fraction with an unrecognized organelle that contained a type II system. However, Lee and coworkers (2006) have clearly shown this to be incorrect. Instead T. brucei "cheats" by using elongation enzymes to make myristate (a relatively short chain fatty acid). This is a surprise because elongases are normally used to extend long chain fatty acids (e.g., extend C18 to C26). Hence, T. brucei uses what would be called a type III system except that the responsible enzymes are homologs of the well-characterized elongase enzymes of mammals and yeast. Lee et al. (2006) focused on the T. brucei elongase pathway for several reasons. First, the membrane localization of myristate production seemed to preclude involvement of a type I megasynthase Morita et al., 2000) . This was confirmed by the recently completed T. brucei genome sequence in which no genes encoding a type I megasynthase are present. However, the genome does include four candidate genes that are homologous to the ELO genes known to encode microsomal elongase enzymes in vertebrates and in yeast. Taken together these data suggested that fatty acid synthesis in T. brucei proceeds by an elongase mechanism. To eliminate the possibility of an organellar type II system, the authors efficiently reduced the expression of the key ACP component of the type II system using RNA interference (RNAi). This had no effect on myristate synthesis assayed in vitro. In contrast, a quantitatively less impressive knockdown of ELO1 expression almost completely blocked myristate synthesis. The authors then went on to construct genomic deletion mutations of each of the four ELO genes. Using membrane preparations derived from these deletion mutants, the synthesis of myristate was shown to require both ELO1 and ELO2 with the former enzyme being responsible for elongation of the C4 primer to C10 whereas the latter enzyme catalyzes the last two C2 additions to give myristate. ELO3 elongates myristoyl-CoA to C16 and C18 and thus seems to work at crosspurposes to myristate production. However, in vivo ELO3 would presumably be competing for myristoyl-CoA with the enzymes catalyzing transfer of myristate into glycosylphosphatidylinositol anchors, or this enzyme could be downregulated. ELO4 seems completely unconnected from myristate production in that it elongates arachidonoyl-CoA to a C22 polyunsaturated species.
Several major questions remain. First, does an ELO2 mutant strain accumulate VSGs anchored by GPIs with abnormally short fatty acids? If so, the VSGs tethered by these anchors must be functional in evading host immunity because the ELO mutant strains remain pathogenic (Lee et al., 2006) . Second, what is the source of the butyrylCoA primer? Although butyrate produced by gut microbes is present in blood, T. brucei seems unable to assimilate this acid (Morita et al., 2000) . Hence, production by catabolism of some molecule abundant in blood seems more likely. Third, is this elongation pathway used by the organism to make membrane lipid acyl chains? This seems to be the case in the tsetse fly form of T. brucei because RNAi knockdown of expression of a microsomal enoyl reductase homolog prevented growth of the parasite (Lee et al., 2006) . However, this may not be the case for the blood form because it dwells in a very lipid-rich environment. Finally, the pathway appears regulated by the lipid content of the medium at least in the tsetse fly form of the parasite (Lee et al., 2006) . Given that the use of elongases in synthesizing fatty acids is conserved among trypanosomes (Lee et al., 2006) , this study has significantly widened our understanding of the mechanisms of fatty acid synthesis.
Modulation of cell shape is a key process that drives morphogenesis during development. For example, in the Drosophila embryo, constriction of the apical epithelial surface during gastrulation results in invagination ( Figure 1A) , whereas more complex cell shape changes give rise to other structures such as grooves and tubes. Within the plane of an epithelial sheet, regulated cell shape-as defined by the polygonal character of the cells in two dimensions-is critical to the formation of some tissues. How these polygonal shapes form is a fascinating question. In a recent study in Nature, Gibson et al. (2006) address this question in the proliferating wingdisc epithelium of Drosophila.
Achieving a particular polygonal cell shape is not simply a consequence of optimal cell packing (see Figure 1) A specific and unexpected distribution pattern of polygonal cell shapes in proliferating epithelia is revealed in a recent study that combines mathematical modeling with experimental data (Gibson et al., 2006) . This pattern is conserved in epithelia from diverse species, suggesting that this distribution is a fundamental property of proliferating epithelial sheets. 
